CGAS and myeloid sarcoma: The enzyme cGAS, which initiates the pathway, is downregulated during the relapse phase of MS, with significantly lower amounts of MB21D1 transcripts (ΔΔCt 3.18 ± 0.62 relapse group) compared to the remission group (ΔΔCt 0.70 ± 0.34) (Figure 5A).